Special Issue "Platelets and Cancer"

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: 30 September 2019

Special Issue Editors

Guest Editor
Prof. Dr. Paola Patrignani

Department of Neuroscience, Imaging and Clinical Sciences, Laboratory of Systems Pharmacology and Translational Therapeutics, Center for Research on Aging and Translational Medicine (CeSI-MeT), 'G. D'Annunzio' University, Via dei Vestini, 31, 66100 Chieti, Italy
Website | E-Mail
Interests: Platelets; colorectal cancer; metastasis; antiplatelet drugs; aspirin; P2Y12 antagonists; eicosanoids
Guest Editor
Dr. Annalisa Bruno

Department of Neuroscience, Imaging and Clinical Sciences, Laboratory of Systems Pharmacology and Translational Therapeutics, Center for Research on Aging and Translational Medicine (CeSI-MeT), 'G. D'Annunzio' University, Via dei Vestini, 31, 66100 Chieti, Italy
E-Mail
Interests: animal models of tumorigenesis and metastasis; intestinal inflammation; transgenic models in pharmacology
Guest Editor
Dr. Melania Dovizio

Department of Neuroscience, Imaging and Clinical Sciences, Laboratory of Systems Pharmacology and Translational Therapeutics, Center for Research on Aging and Translational Medicine (CeSI-MeT), 'G. D'Annunzio' University, Via dei Vestini, 31, 66100 Chieti, Italy
E-Mail
Interests: platelet-microparticles; liquid biopsy; tumor microenvironment; proteomics

Special Issue Information

Dear Colleagues,

Platelets, cytoplasmic fragments of megakaryocytes, are characterized by the absence of a nucleus and the presence of various granules (α-granules, dense granules, and lysosomes). These cell fragments are known for the role played in hemostasis and thrombosis. Platelet activation and aggregation, and the secretion of lipids, including thromboxane(TX)A2, and their granule content [rich in pro-aggregatory molecules like adenosine diphosphate (ADP)] are key events for clotting formation and stop bleeding. Moreover, to their central role in hemostasis and thrombosis platelets are implicated in: (i) inflammation; (ii) immune function; and (iii) pathogenic mechanisms, e.g., atherothrombosis, cancer and metastasis.

The role of platelets in cancer, particularly in tumor metastasis, was first suggested a long time ago, but convincing evidence was recently provided by the analyses of the vast amount of clinical information from placebo-controlled randomized clinical trials (RCTs) with aspirin for cardiovascular prevention.  The evidence was considered appropriate to recommend aspirin use for the primary prevention of cardiovascular disease and cancer by the U.S. Preventive Services Task Force.

The clinical data showing the efficacy of the antiplatelet agent aspirin as an anticancer agent, have catalyzed the work of researchers with different expertise who have uncovered the multifaceted roles played by platelets in tumor development and metastatic dissemination. Platelets act through the crosstalk with stromal cells and cancer cells mediated by the release of several soluble mediators and vesicles, including microparticles.

The biomedical research should exploit the new knowledge on the role of platelets in cancer and focus on the development of safer antiplatelet drugs that interfere with the molecular mechanisms involved in the crosstalk of platelets with the cells of the microenvironment and/or tumor cells. These new pharmacological agents may potentially stop cancer at the earliest stages of development, thus preventing tumor metastasis. Finally, the recent knowledge of the role of platelets in tumor immune escape opens the way to novel strategies to fight cancer based on the use of antiplatelet agents.

The evaluation of proteomics and transcriptomics signature of platelets and platelet-derived microparticles could represent a new strategy for the development of biomarkers for early cancer detection and/or therapeutic drug monitoring in cancer chemotherapy.

Due to the ability of platelets to interact with cancer cells and to deliver their cargo, platelets have been proposed as a “biomimetic drug delivery system” for anti-tumor drugs to prevent the occurrence of off-target adverse events associated with the use of traditional chemotherapy.

Prof. Dr. Paola Patrignani
Dr. Annalisa Bruno
Dr. Melania Dovizio
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers

This special issue is now open for submission.
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top